Back To Search Results

Chorea

Editor: Juan Carlos Sánchez-Manso Updated: 7/10/2023 2:32:29 PM

Introduction

According to the Committee on Classification of the World Federation of Neurology, chorea is defined as "a state of excessive, spontaneous movements, irregularly timed, non-repetitive, randomly distributed and abrupt in character. These movements may vary in severity from restlessness with mild intermittent exaggeration of gesture and expression, fidgeting movements of the hands, unstable dance-like gait to a continuous flow of disabling, violent movements." Chorea, similar to choreography, refers to movements that resemble dancing. [1][2][3][4][5]

Chorea usually is accompanied by athetosis and ballism. Athetosis is a slower form of chorea. The slowed movements have a writhing or twisting motion. Ballism is a very severe form of chorea where there is violent flinging of the extremities. The movements are involuntary and usually involve the limbs. Ballismus is usually unilateral but, rarely, may be bilateral.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Chorea classically is described in Huntington disease, but there are other disorders that can lead to chorea. Spinocerebellar ataxia subtypes, Wilson disease, Sydenham chorea, and structural disease of the basal ganglia can also be associated with chorea. Overall, the root of the pathology is in the basal ganglia, often exemplified by neuro-imaging demonstrating atrophy of the caudate nucleus. Huntington disease is a hereditary cause of chorea and is one of the tri-nucleotide repeat disorders. Huntington disease is caused by a CAG repeat on chromosome 4 in the Huntington, or HTT gene. [6][7][8]

Other Causes

  • Endocrine and metabolic: hypoglycemia, hyperthyroidism, kernicterus, hypomagnesemia
  • Infectious: rheumatic fever, syphilis, subacute sclerosing panencephalitis, Lyme disease, toxoplasmosis, HIV, endocarditis
  • Drugs: levodopa, oral contraceptive, neuroleptics, antihistamines, cocaine, amphetamine, tricyclics
  • Toxins: CO poisoning, mercury, alcohol intoxication
  • Neurologic: stroke, migraine
  • Vascular: polycythemia, Churg Strauss, SLE, Behcet, Multiple sclerosis
  • Malignant: primary brain tumors and metastatic lesion

Epidemiology

While the incidence of chorea in specific disorders is known, the global incidence of chorea is lacking. The incidence of chorea in some common disorders is as follows:

  • Huntington disease is a neurodegenerative autosomal dominant disorder with a prevalence of about 5-10 cases per 100,000 individuals in the US. The disorder is most common in Caucasians but is now being seen in expats who have settled in South and Central America.
  • Wilson disease is a multisystem disorder that is autosomal recessive and has a prevalence of about 30 cases per million people.
  • Benign hereditary chorea is a rare disorder with autosomal dominant inheritance with a prevalence of 1 case per half a million people.

Age

Chorea can occur at any age. In young people, the most common causes of chorea are infections, trauma, and inflammatory causes. 

Huntington chorea usually presents in the fourth to fifth decade of life and is progressive. It is rarely seen before the third decade of life. Individuals who have early onset of the disorder usually inherit the gene from the father, whereas late onset is most likely due to a gene inherited from the mother.

Pathophysiology

This is a disease that has its roots in genetics. The mutated huntingtin protein contains numerous glutamate residues due to the CAG repeats. It is thought that these mutated HTT proteins will aggregate instead of folding to form functional proteins. This is associated with cellular dysfunction.   

Neurotransmitters involved in chorea, include dopamine, acetylcholine, serotonin,  GABA substance P, and cannabinoids.

History and Physical

The universal feature of patients with chorea is that they exhibit uncontrolled motor impersistence such that they are not able to maintain a steady posture, position, or movement. For example, when asked to grip an object, they will alternately continue to release and squeeze. Another feature is the constant dropping of objects.

Chorea can involve both the distal and proximal muscles. While most patients do have normal muscle tone, a few may have hypotonia

Most commonly, excessive unintentional movements of parts of the body lead to medical consultation. These choreiform movements are clearly visible on observation. Other common findings are motor impersistence of the tongue, where the patient displays an inability to keep the tongue protruded when asked to stick their tongue out. The tongue will dart into and out of the mouth. MRI will display caudate atrophy, exemplified by the widening of the lateral ventricles. Later findings of the disease include cognitive and behavioral symptoms. 

Evaluation

Evaluation of a patient with Huntington disease can include genetic testing, CT/MRI, and a psychiatric evaluation for deficits in cognitive, behavioral, and functional areas. Inquiry about suicidality is important.[9][10][11][12]

PET is often used to assess patients with Huntington chorea and neuroacanthocytosis. Bilateral reduction in metabolism in the putamen and the caudate nucleus is frequently seen. However, the reduction in metabolism may not be seen in patients with benign hereditary chorea.

Treatment / Management

There is no cure for this disease; however, symptoms can be managed. Perhaps most important is evaluation and creation of a patient's support system. As the disease progresses, the patient will need specialized caregiving. Nutrition management is important, due to difficulty swallowing. Tetrabenazine has been approved for treatment of chorea. 

Medical Care

The majority of patients are treated with neuroleptics, which block dopamine receptors. Other drugs that are used include GABaergic agents like valproate, clonazepam, and gabapentin. Both minocycline and CoQ10 have shown promise in animals. Chorea that occurs following heart transplant may respond to steroids, and plasmapheresis may shorten the course of chorea in patients with rheumatic fever. For the most part, drugs only reduce the chorea in a few patients, and they also have potent adverse effects.

Surgery

In the past decade, deep brain stimulation (DBS) has been developed and may provide some benefit to some patients with chorea. Anecdotal reports indicate that in selected patients, the procedure does work and reduces chorea. DBS is done by placing electrodes in the globus pallidus internus. However, DBS is still an experimental surgical procedure. It does not work in all patients with chorea, and the procedure is associated with a number of complications.

Neural cell transplantation is another experimental procedure which has been used to treat a few patients with Huntington chorea, but the improvement has not been seen in all patients.

Differential Diagnosis

  • Huntington disease
  • Lesch-Nyhan disease
  • Lyme disease
  • Multiple system atrophy
  • Neuroacanthocytosis
  • Pediatric torticollis surgery
  • Ramsay Hunt syndrome
  • Striatonigral degeneration
  • Tourette syndrome
  • Viral encephalitis

Prognosis

The prognosis of chorea depends on the cause. The majority of patients with Huntington chorea have a poor prognosis and will die prematurely. The same applies to patients with neuroacanthocytosis. When the involuntary movements are severe, this may result in localized trauma or rhabdomyolysis.

In patients with neuroacanthocytosis and those who develop tongue dystonia, swallowing may be affected, resulting in loss of body weight, recurrent episodes of aspiration pneumonia, and even death.

Pearls and Other Issues

Huntington's disease, neuroacanthocytosis, and Wilson disease are genetic disorders hence counseling should be provided to any couple who plans to conceive, especially if one partner has the disorder.

  • Genetic testing should be offered to any family member if they want to know the potential risk of inheriting the disease

  • Educate all patients on the clinical features of the disease options for treatment and prognosis.

Enhancing Healthcare Team Outcomes

The management of chorea is complex because there is no cure. All the currently available treatments are palliative which only manage the symptoms. While the patients are primarily managed by the neurologist, the follow up maybe by the primary care provider and nurse practitioner. The most important is feature is the creation of the patient's support system. As the disease progresses, the patient will need specialized caregiving. Nutrition management is important, due to difficulty swallowing. Genetic testing should be offered to any family member if they want to know the potential risk of inheriting the disease. Educate all patients on the clinical features of the disease options for treatment and prognosis. The prognosis for most patients is poor and the quality of life is markedly diminished.[13] (Level V)

References


[1]

Mehta S, Goyal MK, Kilbane C, Kumar R, Lal V. An Unusual and Intriguing Presentation of Sydenham's Chorea. Tremor and other hyperkinetic movements (New York, N.Y.). 2018:8():593. doi: 10.7916/D8VM5W0N. Epub 2018 Oct 9     [PubMed PMID: 30783549]


[2]

Vasudevan V, Laway BA, Wani AI, Wani MM. Chorea Associated with Nonketotic Hyperglycemia (Diabetic Striatopathy) in an Elderly Male. Indian journal of endocrinology and metabolism. 2018 Nov-Dec:22(6):859-860. doi: 10.4103/ijem.IJEM_314_18. Epub     [PubMed PMID: 30766836]


[3]

Delhasse S, Debove I, Arnold-Kunz G, Ghika JA, Chabwine JN. Erratic movement disorders disclosing Graves' disease and paralleling thyroid function but not autoantibody levels. The Journal of international medical research. 2019 Mar:47(3):1378-1386. doi: 10.1177/0300060518816873. Epub 2019 Feb 14     [PubMed PMID: 30761931]


[4]

Crosiers D, Blaumeiser B, Van Goethem G. Spectrum of Movement Disorders in 18p Deletion Syndrome. Movement disorders clinical practice. 2019 Jan:6(1):70-73. doi: 10.1002/mdc3.12707. Epub 2018 Dec 6     [PubMed PMID: 30746419]


[5]

Parnes M, Bashir H, Jankovic J. Is Benign Hereditary Chorea Really Benign? Brain-Lung-Thyroid Syndrome Caused by NKX2-1 Mutations. Movement disorders clinical practice. 2019 Jan:6(1):34-39. doi: 10.1002/mdc3.12690. Epub 2018 Nov 9     [PubMed PMID: 30746413]


[6]

Rajan S, Kaas B, Moukheiber E. Movement Disorders Emergencies. Seminars in neurology. 2019 Feb:39(1):125-136. doi: 10.1055/s-0038-1677050. Epub 2019 Feb 11     [PubMed PMID: 30743298]


[7]

Weber J, Frings L, Rijntjes M, Urbach H, Fischer J, Weiller C, Meyer PT, Klebe S. Chorea-Acanthocytosis Presenting as Autosomal Recessive Epilepsy in a Family With a Novel VPS13A Mutation. Frontiers in neurology. 2018:9():1168. doi: 10.3389/fneur.2018.01168. Epub 2019 Jan 9     [PubMed PMID: 30687222]


[8]

Klebe S, Timmann D. [Genetics of movement disorders-rare but important]. Der Nervenarzt. 2019 Feb:90(2):197-210. doi: 10.1007/s00115-018-0659-1. Epub     [PubMed PMID: 30645659]


[9]

Bashir H, Jankovic J. Treatment options for chorea. Expert review of neurotherapeutics. 2018 Jan:18(1):51-63. doi: 10.1080/14737175.2018.1403899. Epub 2017 Nov 15     [PubMed PMID: 29120264]


[10]

Yapijakis C. Huntington Disease: Genetics, Prevention, and Therapy Approaches. Advances in experimental medicine and biology. 2017:987():55-65. doi: 10.1007/978-3-319-57379-3_6. Epub     [PubMed PMID: 28971447]

Level 3 (low-level) evidence

[11]

van Duijn E. Medical treatment of behavioral manifestations of Huntington disease. Handbook of clinical neurology. 2017:144():129-139. doi: 10.1016/B978-0-12-801893-4.00011-0. Epub     [PubMed PMID: 28947111]


[12]

Litwin T, Dušek P, Członkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handbook of clinical neurology. 2017:142():211-223. doi: 10.1016/B978-0-444-63625-6.00018-5. Epub     [PubMed PMID: 28433105]


[13]

Carlozzi NE, Schilling S, Kratz AL, Paulsen JS, Frank S, Stout JC. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2018 Oct:27(10):2541-2555. doi: 10.1007/s11136-018-1912-6. Epub 2018 Jun 16     [PubMed PMID: 29909483]

Level 2 (mid-level) evidence